Free Trial

Stoke Therapeutics (STOK) Stock Price, News & Analysis

Stoke Therapeutics logo
$29.90 -0.60 (-1.97%)
Closing price 10/9/2025 04:00 PM Eastern
Extended Trading
$29.96 +0.06 (+0.20%)
As of 10/9/2025 07:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Stoke Therapeutics Stock (NASDAQ:STOK)

Advanced

Key Stats

Today's Range
$29.80
$31.99
50-Day Range
$12.91
$30.50
52-Week Range
$5.35
$32.40
Volume
1.36 million shs
Average Volume
1.21 million shs
Market Capitalization
$1.64 billion
P/E Ratio
35.18
Dividend Yield
N/A
Price Target
$25.57
Consensus Rating
Buy

Company Overview

Stoke Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
61st Percentile Overall Score

STOK MarketRank™: 

Stoke Therapeutics scored higher than 61% of companies evaluated by MarketBeat, and ranked 347th out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Stoke Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and 1 sell rating.

  • Downside Risk

    Stoke Therapeutics has a consensus price target of $25.57, representing about 14.5% downside from its current price of $29.90.

  • Amount of Analyst Coverage

    Stoke Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Stoke Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Stoke Therapeutics are expected to decrease in the coming year, from ($2.01) to ($2.27) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Stoke Therapeutics is 35.18, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 233.94.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Stoke Therapeutics is 35.18, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 85.84.

  • Price to Book Value per Share Ratio

    Stoke Therapeutics has a P/B Ratio of 6.92. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Stoke Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    20.78% of the outstanding shares of Stoke Therapeutics have been sold short.
  • Short Interest Ratio / Days to Cover

    Stoke Therapeutics has a short interest ratio ("days to cover") of 13.1, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Stoke Therapeutics has recently increased by 6.05%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Stoke Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Stoke Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    20.78% of the outstanding shares of Stoke Therapeutics have been sold short.
  • Short Interest Ratio / Days to Cover

    Stoke Therapeutics has a short interest ratio ("days to cover") of 13.1, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Stoke Therapeutics has recently increased by 6.05%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Stoke Therapeutics has a news sentiment score of 0.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.77 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 21 news articles for Stoke Therapeutics this week, compared to 6 articles on an average week.
  • Search Interest

    Only 24 people have searched for STOK on MarketBeat in the last 30 days. This is a decrease of -4% compared to the previous 30 days.
  • MarketBeat Follows

    3 people have added Stoke Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Stoke Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,379,406.00 in company stock.

  • Percentage Held by Insiders

    Only 9.50% of the stock of Stoke Therapeutics is held by insiders.

  • Read more about Stoke Therapeutics' insider trading history.
Receive STOK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Stoke Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

STOK Stock News Headlines

What if your job didn’t matter — and neither did China’s chip ban?
If you’ve been watching the headlines lately…You’ve seen how Nvidia and AMD just got the green light to resume chip exports to China. That news sent their stocks flying. But here’s the truth: By the time the market reacts to big news, most traders are too late.tc pixel
Stoke Therapeutics Appoints Smith as Permanent CEO
See More Headlines

STOK Stock Analysis - Frequently Asked Questions

Stoke Therapeutics' stock was trading at $11.03 at the start of the year. Since then, STOK stock has increased by 171.1% and is now trading at $29.90.

Stoke Therapeutics, Inc. (NASDAQ:STOK) issued its quarterly earnings data on Tuesday, August, 12th. The company reported ($0.40) EPS for the quarter, topping the consensus estimate of ($0.57) by $0.17. The company had revenue of $13.82 million for the quarter, compared to analyst estimates of $31.51 million. Stoke Therapeutics had a trailing twelve-month return on equity of 18.32% and a net margin of 26.25%.
Read the conference call transcript
.

Stoke Therapeutics (STOK) raised $100 million in an initial public offering (IPO) on Wednesday, June 19th 2019. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Cowen and Credit Suisse served as the underwriters for the IPO and Canaccord Genuity was co-manager.

Top institutional investors of Stoke Therapeutics include Assenagon Asset Management S.A. (1.64%). Insiders that own company stock include Skorpios Trust, Edward M Md Kaye, Stephen J Tulipano, Barry Ticho and Jonathan Allan.
View institutional ownership trends
.

Shares of STOK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Stoke Therapeutics investors own include Enovix (ENVX), Rambus (RMBS), COMPASS Pathways (CMPS), Globant (GLOB), Ginkgo Bioworks (DNA), Toast (TOST) and Saia (SAIA).

Company Calendar

Last Earnings
8/12/2025
Today
10/10/2025
Next Earnings (Estimated)
11/04/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:STOK
CIK
1623526
Fax
N/A
Employees
100
Year Founded
2014

Price Target and Rating

High Price Target
$35.00
Low Price Target
$18.00
Potential Upside/Downside
-14.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
10 Analysts

Profitability

EPS (Trailing Twelve Months)
$0.85
Trailing P/E Ratio
35.18
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$88.98 million
Net Margins
26.25%
Pretax Margin
26.90%
Return on Equity
18.32%
Return on Assets
15.48%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
6.98
Quick Ratio
6.98

Sales & Book Value

Annual Sales
$199.89 million
Price / Sales
8.20
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$4.32 per share
Price / Book
6.92

Miscellaneous

Outstanding Shares
54,797,000
Free Float
49,591,000
Market Cap
$1.64 billion
Optionable
Optionable
Beta
1.24

Social Links

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

This page (NASDAQ:STOK) was last updated on 10/10/2025 by MarketBeat.com Staff
From Our Partners